Cargando…

Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan

Study Objectives: Diabetes mellitus per se and its related therapy have been frequently associated with an increased risk of developing dementia. However, studies that explored the risk of dementia from the use of the novel oral antidiabetic medication dipeptidyl peptidase 4 inhibitor (DPP-4i) have...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kuan-Chan, Chung, Chi-Hsiang, Lu, Chieh-Hua, Tzeng, Nian-Sheng, Lee, Chien-Hsing, Su, Sheng-Chiang, Kuo, Feng-Chih, Liu, Jhih-Syuan, Hsieh, Chang-Hsun, Chien, Wu-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141309/
https://www.ncbi.nlm.nih.gov/pubmed/32121372
http://dx.doi.org/10.3390/jcm9030660
_version_ 1783519169838317568
author Chen, Kuan-Chan
Chung, Chi-Hsiang
Lu, Chieh-Hua
Tzeng, Nian-Sheng
Lee, Chien-Hsing
Su, Sheng-Chiang
Kuo, Feng-Chih
Liu, Jhih-Syuan
Hsieh, Chang-Hsun
Chien, Wu-Chien
author_facet Chen, Kuan-Chan
Chung, Chi-Hsiang
Lu, Chieh-Hua
Tzeng, Nian-Sheng
Lee, Chien-Hsing
Su, Sheng-Chiang
Kuo, Feng-Chih
Liu, Jhih-Syuan
Hsieh, Chang-Hsun
Chien, Wu-Chien
author_sort Chen, Kuan-Chan
collection PubMed
description Study Objectives: Diabetes mellitus per se and its related therapy have been frequently associated with an increased risk of developing dementia. However, studies that explored the risk of dementia from the use of the novel oral antidiabetic medication dipeptidyl peptidase 4 inhibitor (DPP-4i) have been limited, especially in Asian populations. The present study aimed to determine the effect of DPP-4i on the subsequent risk of dementia among patients with type 2 diabetes (T2D) in Taiwan. Methods: This study utilized data from the Longitudinal Health Insurance Database between 2008 and 2015. We enrolled 2903 patients aged ≥50 years, who were on DPP-4i for a diagnosis of T2D and had no dementia. A total of 11,612 subjects were included and compared with a propensity score-matched control group who did not use DPP-4i (non-DPP-4i group). Survival analysis was performed to estimate and compare the risk of dementia—including Alzheimer’s disease, vascular dementia, and other dementia types—between the two groups. Results: Both groups had a mean age of 68 years, had a preponderance of women (61.8%), and were followed up for a mean duration of 7 years. The risk of all-cause dementia was significantly lower in the DPP-4i group than in the non-DPP-4i group (hazard ratio (HR) 0.798; 95% confidence interval (CI) 0.681–0.883; p < 0.001), with a class effect. This trend was particularly observed for vascular dementia (HR 0.575; 95% CI 0.404–0.681; p < 0.001), but not in Alzheimer’s disease (HR 0.891; 95% CI 0.712–1.265; p = 0.297). The Kaplan–Meier analysis showed that the preventive effect on dementia was positively correlated with the cumulative dose of DPP-4i. Conclusions: DPP-4i decreased the risk of dementia with a class effect, especially vascular dementia, but not in Alzheimer’s disease. Our results provide important information on the drug choice when managing patients with T2D in clinical practice.
format Online
Article
Text
id pubmed-7141309
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71413092020-04-10 Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan Chen, Kuan-Chan Chung, Chi-Hsiang Lu, Chieh-Hua Tzeng, Nian-Sheng Lee, Chien-Hsing Su, Sheng-Chiang Kuo, Feng-Chih Liu, Jhih-Syuan Hsieh, Chang-Hsun Chien, Wu-Chien J Clin Med Article Study Objectives: Diabetes mellitus per se and its related therapy have been frequently associated with an increased risk of developing dementia. However, studies that explored the risk of dementia from the use of the novel oral antidiabetic medication dipeptidyl peptidase 4 inhibitor (DPP-4i) have been limited, especially in Asian populations. The present study aimed to determine the effect of DPP-4i on the subsequent risk of dementia among patients with type 2 diabetes (T2D) in Taiwan. Methods: This study utilized data from the Longitudinal Health Insurance Database between 2008 and 2015. We enrolled 2903 patients aged ≥50 years, who were on DPP-4i for a diagnosis of T2D and had no dementia. A total of 11,612 subjects were included and compared with a propensity score-matched control group who did not use DPP-4i (non-DPP-4i group). Survival analysis was performed to estimate and compare the risk of dementia—including Alzheimer’s disease, vascular dementia, and other dementia types—between the two groups. Results: Both groups had a mean age of 68 years, had a preponderance of women (61.8%), and were followed up for a mean duration of 7 years. The risk of all-cause dementia was significantly lower in the DPP-4i group than in the non-DPP-4i group (hazard ratio (HR) 0.798; 95% confidence interval (CI) 0.681–0.883; p < 0.001), with a class effect. This trend was particularly observed for vascular dementia (HR 0.575; 95% CI 0.404–0.681; p < 0.001), but not in Alzheimer’s disease (HR 0.891; 95% CI 0.712–1.265; p = 0.297). The Kaplan–Meier analysis showed that the preventive effect on dementia was positively correlated with the cumulative dose of DPP-4i. Conclusions: DPP-4i decreased the risk of dementia with a class effect, especially vascular dementia, but not in Alzheimer’s disease. Our results provide important information on the drug choice when managing patients with T2D in clinical practice. MDPI 2020-02-29 /pmc/articles/PMC7141309/ /pubmed/32121372 http://dx.doi.org/10.3390/jcm9030660 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Kuan-Chan
Chung, Chi-Hsiang
Lu, Chieh-Hua
Tzeng, Nian-Sheng
Lee, Chien-Hsing
Su, Sheng-Chiang
Kuo, Feng-Chih
Liu, Jhih-Syuan
Hsieh, Chang-Hsun
Chien, Wu-Chien
Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
title Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
title_full Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
title_fullStr Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
title_full_unstemmed Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
title_short Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
title_sort association between the use of dipeptidyl peptidase 4 inhibitors and the risk of dementia among patients with type 2 diabetes in taiwan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141309/
https://www.ncbi.nlm.nih.gov/pubmed/32121372
http://dx.doi.org/10.3390/jcm9030660
work_keys_str_mv AT chenkuanchan associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT chungchihsiang associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT luchiehhua associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT tzengniansheng associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT leechienhsing associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT sushengchiang associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT kuofengchih associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT liujhihsyuan associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT hsiehchanghsun associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan
AT chienwuchien associationbetweentheuseofdipeptidylpeptidase4inhibitorsandtheriskofdementiaamongpatientswithtype2diabetesintaiwan